Stocks and InvestingStocks and Investing
Fri, June 4, 2021
Thu, June 3, 2021
Wed, June 2, 2021
Tue, June 1, 2021
Fri, May 28, 2021

David Lebowitz Maintained (ASND) at Buy with Increased Target to $201 on, May 28th, 2021


Published on 2024-10-27 16:50:23 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Morgan Stanley, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $199 to $201 on, May 28th, 2021.

David has made no other calls on ASND in the last 4 months.



There are 2 other peers that have a rating on ASND. Out of the 2 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Tuesday, March 30th, 2021


This is the rating of the analyst that currently disagrees with David


  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $190 on, Friday, March 12th, 2021